Merck: Exploiting Erbitux
Merck KGAA's fortunes are tied precariously to the industry's most controversial product, cancer drug Erbitux. Since it relies on Erbitux to fill the gap left by falling Glucophage revenues as well as to spearhead a wider move into oncology, Merck is trying to treat Erbitux's bumpy ride to date as an opportunity, not a threat.
You may also be interested in...
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?